The Enigma of Elevated Donor-Derived Cell-Free DNA with Negative Endomyocardial Biopsy

Purpose: The emergent use of donor-derived cell-free DNA (dd-cfDNA) as a biomarker forearly assessment of allograft injury has rapidly become part of rejection surveillance following hearttransplantation (HT). However, the significance of elevated dd-cfDNA is still nebulous without clinical orhistological evidence of rejection.The aim of the study is to describe the characteristics of patients with elevated dd-cfDNA ( ≥0.12%) inpatients with negative biopsy.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Liotta, S. Marek-Iannucci, G. Gibson, S. Masri, J. Rame, E. Storozynsky, H. Eisen, R. Alvarez, I. Rajapreyar, Y. Brailovsky Source Type: research